Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 10 11:57AM ET
3.66
Dollar change
+0.06
Percentage change
1.52
%
IndexRUT P/E- EPS (ttm)-0.44 Insider Own5.19% Shs Outstand149.00M Perf Week7.16%
Market Cap546.38M Forward P/E- EPS next Y-0.19 Insider Trans0.12% Shs Float141.35M Perf Month5.62%
Income-63.11M PEG- EPS next Q-0.07 Inst Own43.59% Short Float7.18% Perf Quarter28.15%
Sales187.36M P/S2.92 EPS this Y20.54% Inst Trans6.12% Short Ratio6.22 Perf Half Y59.35%
Book/sh-0.19 P/B- EPS next Y47.66% ROA-19.45% Short Interest10.15M Perf Year80.54%
Cash/sh0.47 P/C7.87 EPS next 5Y- ROE-617.16% 52W Range1.69 - 3.87 Perf YTD55.96%
Dividend Est.- P/FCF- EPS past 5Y38.13% ROI-28.49% 52W High-5.30% Beta1.83
Dividend TTM- Quick Ratio1.29 Sales past 5Y195.35% Gross Margin75.57% 52W Low116.86% ATR (14)0.17
Dividend Ex-Date- Current Ratio1.79 EPS Y/Y TTM2.62% Oper. Margin-24.11% RSI (14)65.87 Volatility5.25% 5.70%
Employees377 Debt/Eq- Sales Y/Y TTM22.72% Profit Margin-33.69% Recom1.33 Target Price4.77
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q-19.59% Payout- Rel Volume1.11 Prev Close3.61
Sales Surprise2.75% EPS Surprise-26.87% Sales Q/Q12.31% EarningsNov 08 BMO Avg Volume1.63M Price3.66
SMA2012.07% SMA5015.81% SMA20045.02% Trades Volume737,425 Change1.52%
Date Action Analyst Rating Change Price Target Change
Nov-11-24Downgrade Piper Sandler Overweight → Neutral $3
Mar-28-24Initiated Oppenheimer Outperform $5
Aug-28-23Initiated Craig Hallum Buy $4.50
Oct-21-22Initiated Jefferies Buy $4
Apr-28-22Initiated Craig Hallum Buy $6.50
Nov-17-21Initiated SVB Leerink Outperform $6
Oct-29-21Initiated H.C. Wainwright Buy $4
Apr-07-21Resumed RBC Capital Mkts Outperform $11
Feb-18-20Initiated Piper Sandler Overweight $12
Jul-16-18Initiated RBC Capital Mkts Outperform $24
Nov-26-24 07:00AM
Nov-09-24 02:06AM
Nov-08-24 09:30AM
08:10AM
07:10AM
07:00AM Loading…
07:00AM
Oct-31-24 08:00AM
Oct-04-24 04:05PM
Aug-22-24 07:00AM
Aug-08-24 08:25AM
07:30AM
07:00AM
Aug-01-24 10:01AM
Jul-25-24 07:00AM
Jul-24-24 09:55AM
07:00AM Loading…
Jul-08-24 07:00AM
Jul-03-24 01:05PM
Jun-03-24 07:00AM
May-30-24 07:30AM
07:00AM
May-10-24 03:21PM
12:36PM
12:27AM
May-09-24 11:55AM
08:10AM
07:11AM
07:00AM
May-06-24 07:42AM
07:00AM
May-02-24 07:00AM
04:05PM Loading…
Apr-03-24 04:05PM
Apr-02-24 07:00AM
Mar-07-24 01:47PM
11:56AM
Mar-06-24 11:16PM
12:52PM
08:15AM
07:17AM
07:02AM
07:00AM
Mar-05-24 09:42AM
Feb-28-24 07:00AM
Feb-05-24 07:00AM
Jan-11-24 08:30AM
Jan-10-24 08:00AM
Jan-08-24 02:48PM
Jan-05-24 04:05PM
Jan-04-24 07:00AM
Dec-27-23 07:00AM
Dec-23-23 07:32PM
Dec-20-23 02:00PM
Nov-17-23 01:07PM
Nov-10-23 04:00PM
01:53AM
Nov-09-23 11:30AM
08:10AM
07:17AM
07:00AM
Oct-26-23 06:15PM
Oct-16-23 07:00AM
Sep-27-23 08:00AM
Sep-20-23 07:36AM
Sep-14-23 04:05PM
Aug-28-23 07:00AM
Aug-17-23 11:00AM
Aug-11-23 09:09AM
Aug-10-23 11:59AM
Aug-08-23 12:05PM
09:15AM
07:13AM
07:00AM
Aug-01-23 07:00AM
Jul-31-23 07:00AM
Jun-29-23 04:19PM
Jun-22-23 01:50PM
Jun-21-23 07:00AM
Jun-19-23 12:58PM
Jun-01-23 07:00AM
May-09-23 11:33PM
07:25AM
07:00AM
May-08-23 06:37AM
May-02-23 07:00AM
Apr-18-23 07:00AM
Apr-17-23 06:25AM
Apr-06-23 08:21AM
Apr-05-23 01:18PM
Mar-30-23 07:00AM
Mar-29-23 04:05PM
Mar-08-23 11:52PM
06:00AM
Feb-23-23 07:00AM
Feb-02-23 07:00AM
Jan-30-23 07:00AM
Jan-05-23 04:03PM
07:00AM
Dec-31-22 09:33AM
Dec-15-22 07:00AM
Nov-24-22 10:56AM
Nov-23-22 06:00AM
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pieper StevenSee RemarksNov 22 '24Option Exercise1.5519,48330,1991,441,820Nov 26 05:00 PM
Schmid John P.DirectorAug 12 '24Buy2.254,51510,14725,200Aug 13 04:15 PM
Schmid John P.DirectorAug 09 '24Buy2.374,28510,13420,685Aug 12 06:28 PM
Schmid John P.DirectorMay 10 '24Buy1.915,40010,31416,400May 10 04:04 PM
JOHNSON JOHNDirectorMar 18 '24Option Exercise1.99215,600429,044751,412Mar 18 05:32 PM
Schmid John P.DirectorMar 14 '24Buy2.164,5009,72011,000Mar 14 09:03 PM